Hiperlipemili Hastalarda Atromid. S,Niacin Ve Cholemine İle Yapılan Mukayeseli Bir Çalışma

Year 1968, Volume: 21 Issue: 4, 1063 - 1071, 31.12.1968

Nurten Meriç

https://izlik.org/JA97LZ65SW

Abstract

Bu çalışmamızda, 35 - 65 yaşları arasında bulunan her iki seksten karışık 32 hiperlipemik vak'a, üç guruba ayrılarak tedaviye tabi tutuldu. Atromid - S tedavisiyle kolesterol (16 vak'a) ve total lipidde (16 vak'a) istatistik bakımından önemli bir düşme, trigliseridde ise (9 vak'a) önemsiz düşme görüldü. Cholemine tedavi gurubunda, kolesterol (11 vak'a) seviyesinde çok önemli, total lipidde ise istatistik bakımından önemsiz düşme, buna karşılık trigliseridde (6 vak'a) yükselme görüldü. Niacin tedavi gurubunda (nicotinic acid) yeterli vak'a bulunamadığı için istatistik bakımından inceleme yapılamadı. Bu son gurupta basit ortalamayla kolesterolde Yo 19,5, total lipidde Yo 7,4 düşmeye karşılık trigliseridde artış bulundu.

Keywords

Hiperlipidemi , Atromid-S tedavisi , Serum lipid düzeyleri

A Comparative Study of Atromid S, Niacin, and Cholemine in Patients with Hyperlipemia

https://izlik.org/JA97LZ65SW

Abstract

İn this study we attempted to treat 32 cases of hyperlipemia with Atromid - S, Cholemine and Niacin. The ages of cases ranged between 35 and 65. 16 cases were given Atromid -S, İl cases were given Cholemine, the rest (5 cases) were given Niacin, Colesterol and total lipid level showed a considerable reduction in cases who had been treated with Atromid - S. While trigiycerid level in this group showed only a statistically insignificant reduction. İn the cases treated with Cholemine cholesterol decreased significantiy. Total lipid showed some reduction but this was not statisticalkly significant. in this group trigiycerid level (6 cases) in- creased during and after treatment.
İn cases treated with Niacin, we colud not evaluate the results since we did not have enough cases for a statıstıcal work -up, İn this last group the average serum cholesterol reducticn was G 19.5 total serum lipid reductıon was 7 7.4 Contrary to serum cholesterol and total linid reduction trigiyeerid level showed mild increase (10.2 G£) during and after treatment.

Keywords

Hyperlipidemia , Atromid-S treatment , Serum lipid levels

References

• 1 — GOLDSMİTH, G.; Therapy of Hypercholesterelemia, Amer. J. Dig. Dıs. 9: 651, 1964
• 2 — TENNET, J.: Plasma cholesterol lowering action of bile acid binding polymers in experimental animals, J. Lipid Res. 1: 469, 1960.
• 3 — BRESSLERR.J.: Treatment of hypereholesterolemlia and hypertrigly- ceridemia by anlon exchange resin, Southern Med. J. 59 : 1097.
• 4 — BAGGENTOSS, A. H.: Fine structural changes in liver in hypercholes- terolemic patients reciving long term Nicotinic acid therapy. Mayo Clin. Proc. 42: 385, 1967.
• 5 — ROHRBACH, MMe LEPRINCE, C.: Etude de T'acide Nicotinigue et guelgue dörivse comme hypolipemiant Thârapie. 21: 1062, 1966.
• 6 — TRIBIANO,C.'W.: Aliminium Nicotinate in the treatment of hyperlipemia. Cur. Therap. Res. 4: 542, 1962.
• 7 — ENGELBERG, J.: Liver functlon studies in humans with elevated levels of serum cholesterol and/or low dansity lipoprotein. Circulation 20: 983, 1959,
• 8-THORP, J. M.: Experimental evaluation of an orally active conıbinaton with ethyl chlorophenoxy isobutyrate. Lancet 1: 1323, 1962.
• 9-OLIVER, M. F.: Reduction of serum lipld and uric acid levels by orally active androsteron. Lancet 1: 1321, 1962.
• 10-ENGSTROM, J.: Clinical trial with ethyl chloro phenoxy isobutyrate (Atromid-$) with special reference to white blood cell count. Acta Med. Scan. 180: 519, 1966.
• 11-OLIVER, M. F.: Further observation on the effects of atromidon serum lipids levels. J. Ather. Res. 3: 427, 1963.
• 12-STRISOVER, E.: The seperate hypolipoproteinemic effects of d-thyronine and ethyl chloro phenoxy isobutyrate. J. Clin. Endoc. 24: 139, 1964
• 13-TANTENGCO, V. D.: Effect of Nicotinic acid, ascorbic acid, trilodothyronin on serum and liver cholesterol levels. Acta Med. Philipp. 3:1, 1966.
• 14-ÖZKAN K, TÜRKVAN M.: Kan serum trigiyserid, kollesterol ve total lipid miktarları, ve Ateroskleroz. Ankara Tıp Fak. Mec. XIX : 521, 1966.
• 15-ASKANAS, Z.: Effect of Atromid on serum lipids and fibrinolysis in myocardial infarction convalescents. (Abstract) Polskie Arch. Med. Wewmnetrznej. 35 : 5, 1965.
• 16-MACMILLAN, D.C.: Effect of CPIB on weight, plasma, total body water and free fatty aclds Lancet HI (7419) : 924, 1965.
• 17-SZNAJDERMAN, M.: Clinical studies of Atromid. The effect on serunı lipids and functional tests of liver (Abstract) Polskie Arch. Med. Wewnetrznej 84 (12) : 1641, 1964.
• 18-FELT, V.: Effect of dehydroeplandrosterone and atromid on serum lipids in patients with hypercholesterolemla. (Chemical Abstract) Casopis Lecaru Ceskyc 104: 186, 1965.
• 19-COTTON, R. C.: Effect of ethyl chlorophenoxy isobutyrate (Atromid) on plazma fibrinojen and serum cholesterol in patlents With iscemic heart disease. J. Atheroscler. Res. 6(1) : 98, 1966.
• 20-TRUSWELL, A. S.: Effect of Atromid-S on the pattern of bile acids in human bils. J. Athero. Res, 6 (6) : 591, 1966.
• 21-GOULD, R. G.: Effects of CPİD on liver composition and trigiyceride synthesis in rats. J. Ather, Res. 6 (6): 555, 1966.
• 22-KELLER, L.: Influence of ethyli chlorophenoxy isobutyrate on serum lipids in coronary scleross (Chemical Abstract) Z. Ges. Inn. Med. Ihre Grenzgebiete 21 (6) : 169, 1966.